- Conditions
- Hidradenitis Suppurativa
- Interventions
- Brivekimig, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Northridge, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- Interventions
- frexalimab, brivekimig, rilzabrutinib, placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 13 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Brivekimig, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Columbus, Georgia • Farmington Hills, Michigan + 2 more